Courtesy of Agilent Technologies
With just a few protein comprising 85% to 90% of human serum, low-abundance components can be difficult to identify by mass spectrometry. Palo Alto, Calif.-based Agilent Technologies
Agilent has optimized the chemistry used to bind the antibodies to the beads, allowing more protein-binding sites to be exposed, explains spokesperson William Barrett. Up to 100 microliters of serum can be cleared per 4.6 mm x 100 mm column, effectively doubling the capacity (previously, the same column could process 30–40 ml).
Beta-tester Tasso Miliotis, associate principal scientist at AstraZeneca, says the high loading capacity allows more plasma to be injected per run, improving the downstream detection of low-abundance proteins. "Previously we had to make triplicate injections of the same...